Should I buy or sell Eledon Pharmaceuticals stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eledon Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ELDN shares. View ELDN analyst ratings or view top-rated stocks .

What is Eledon Pharmaceuticals' stock price target for 2024?

3 brokers have issued 12 month price objectives for Eledon Pharmaceuticals' shares. Their ELDN share price targets range from $9.00 to $13.00. On average, they anticipate the company's share price to reach $10.67 in the next year. This suggests a possible upside of 473.5% from the stock's current price. View analysts price targets for ELDN or view top-rated stocks among Wall Street analysts .

How have ELDN shares performed in 2024?

Eledon Pharmaceuticals' stock was trading at $1.80 at the start of the year. Since then, ELDN stock has increased by 3.3% and is now trading at $1.86. View the best growth stocks for 2024 here .

Are investors shorting Eledon Pharmaceuticals?

Eledon Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 106,900 shares, an increase of 193.7% from the March 15th total of 36,400 shares. Based on an average trading volume of 78,000 shares, the days-to-cover ratio is presently 1.4 days. View Eledon Pharmaceuticals' Short Interest .

When is Eledon Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ELDN earnings forecast .

How were Eledon Pharmaceuticals' earnings last quarter?

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) posted its quarterly earnings data on Thursday, March, 28th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.09.

How do I buy shares of Eledon Pharmaceuticals?

Shares of ELDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ELDN

Eledon Pharmaceuticals (ELDN) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free ELDN Stock Alerts

$1.86

-0.13 (-6.53%)

(As of 04/19/2024 ET)

Compare

Today's Range: $1.77
▼
$2.18
50-Day Range: $1.54
▼
$2.13
52-Week Range: $1.07
▼
$2.95

Volume: 420,318 shs
Average Volume: 84,300 shs
Market Capitalization: $46.15 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.67

Get Eledon Pharmaceuticals alerts:

Eledon Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 473.5% Upside
$10.67 Price Target
Short Interest: Healthy
0.43% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.38) to ($0.88) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.25 out of 5 stars

Medical Sector

512th out of 911 stocks

Pharmaceutical Preparations Industry

227th out of 411 stocks

3.5

Analyst's Opinion

Consensus Rating
Eledon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Eledon Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.43% of the outstanding shares of Eledon Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Eledon Pharmaceuticals has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Eledon Pharmaceuticals has recently increased by 193.68%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Eledon Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Eledon Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ELDN.

1.1

News and Social Media Coverage

Search Interest
8 people have searched for ELDN on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
MarketBeat Follows
5 people have added Eledon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Eledon Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
19.40% of the stock of Eledon Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
56.77% of the stock of Eledon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Eledon Pharmaceuticals are expected to grow in the coming year, from ($1.38) to ($0.88) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Eledon Pharmaceuticals is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Eledon Pharmaceuticals is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Eledon Pharmaceuticals has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Eledon Pharmaceuticals Stock (NASDAQ:ELDN)

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

ELDN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ELDN Stock News Headlines

March 29, 2024 | finanznachrichten.de

Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

March 29, 2024 | msn.com

ELDN Stock Earnings: Eledon Pharma Beats EPS for Q4 2023

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 28, 2024 | globenewswire.com

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

March 25, 2024 | globenewswire.com

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

March 25, 2024 | markets.businessinsider.com

Eledon Pharmaceuticals’ Tegoprubart Shows Best-in-Class Potential in Organ Transplantation

March 21, 2024 | msn.com

Kidney Transplant From Genetically Edited Pig: Boston Patient With End-Stage Renal Disease Becomes First To Receive

March 21, 2024 | finance.yahoo.com

Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

February 19, 2024 | finance.yahoo.com

Eledon Pharmaceuticals, Inc. (ELDN)

February 17, 2024 | morningstar.com

Eledon Pharmaceuticals Inc ELDN

February 13, 2024 | globenewswire.com

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 5, 2024 | finanznachrichten.de

Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

January 5, 2024 | msn.com

Eledon Pharmaceuticals reports recent business milestones

January 4, 2024 | finance.yahoo.com

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

December 25, 2023 | finance.yahoo.com

Will Eledon Pharmaceuticals (NASDAQ:ELDN) Spend Its Cash Wisely?

November 29, 2023 | finance.yahoo.com

Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference

November 10, 2023 | finanznachrichten.de

Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results

November 9, 2023 | msn.com

Eledon Pharmaceuticals, Inc. (ELDN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

November 9, 2023 | finance.yahoo.com

Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results

November 8, 2023 | finance.yahoo.com

Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference

November 6, 2023 | markets.businessinsider.com

Promising Results and Buy Rating for Eledon Pharmaceuticals: Tegoprubart’s Potential in Kidney Transplant Therapy

November 4, 2023 | markets.businessinsider.com

Promising Phase Ib Study Results Bolster Buy Rating for Eledon Pharmaceuticals: An Analysis by Rami Katkhuda

November 2, 2023 | finance.yahoo.com

Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

October 24, 2023 | msn.com

HC Wainwright & Co. Maintains Eledon Pharmaceuticals (ELDN) Buy Recommendation

October 23, 2023 | msn.com

Eledon Pharmaceuticals appoints Eliezer Katz as CMO

October 23, 2023 | markets.businessinsider.com

Eledon Pharmaceuticals Appoints Eliezer Katz As Chief Medical Officer

See More Headlines

Receive ELDN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eledon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/28/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ELDN
CUSIP: N/A
CIK: 1404281
Web: novustherapeutics.com
Phone: (949) 238-8090
Fax: N/A
Employees: 17
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.67
High Stock Price Target: $13.00
Low Stock Price Target: $9.00
Potential Upside/Downside: +449.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.79)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-40,330,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -46.15%
Return on Assets: -43.10%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 14.41
Quick Ratio: 14.41

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.45 per share
Price / Book: 0.56

Miscellaneous

Outstanding Shares: 24,810,000
Free Float: 19,999,000
Market Cap: $48.13 million
Optionable: Optionable
Beta: 0.87

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. David-Alexandre C. Gros M.D. (Age 52)
Ph.D., CEO & Non Independent Director
Comp: $807.96k
Dr. Steven N. Perrin Ph.D. (Age 58)
President, Chief Scientific Officer & Non Independent Director
Comp: $603.9k
Mr. Paul Sean Little (Age 59)
CFO & Principal Accounting Officer
Comp: $611.71k
Mr. John Herberger
Vice President of Technical Operations
Mr. Bryan E. Smith J.D. (Age 44)
General Counsel, Corporate Secretary & Chief Compliance Officer
Comp: $377.14k
Dr. David Hovland Ph.D.
Chief Regulatory Officer
Dr. Eliezer Katz F.A.C.S.
FACS, M.D., Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ELDN Stock Analysis - Frequently Asked Questions

Should I buy or sell Eledon Pharmaceuticals stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eledon Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ELDN shares.
View ELDN analyst ratings or view top-rated stocks.
What is Eledon Pharmaceuticals' stock price target for 2024?: 3 brokers have issued 12 month price objectives for Eledon Pharmaceuticals' shares. Their ELDN share price targets range from $9.00 to $13.00. On average, they anticipate the company's share price to reach $10.67 in the next year. This suggests a possible upside of 473.5% from the stock's current price.
View analysts price targets for ELDN or view top-rated stocks among Wall Street analysts.
How have ELDN shares performed in 2024?: Eledon Pharmaceuticals' stock was trading at $1.80 at the start of the year. Since then, ELDN stock has increased by 3.3% and is now trading at $1.86.
View the best growth stocks for 2024 here.
Are investors shorting Eledon Pharmaceuticals?: Eledon Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 106,900 shares, an increase of 193.7% from the March 15th total of 36,400 shares. Based on an average trading volume of 78,000 shares, the days-to-cover ratio is presently 1.4 days.
View Eledon Pharmaceuticals' Short Interest.

When is Eledon Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ELDN earnings forecast.
How were Eledon Pharmaceuticals' earnings last quarter?: Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) posted its quarterly earnings data on Thursday, March, 28th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.09.
How do I buy shares of Eledon Pharmaceuticals?: Shares of ELDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ELDN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Eledon Pharmaceuticals (ELDN) Stock Price, News & Analysis

Eledon Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Eledon Pharmaceuticals Stock (NASDAQ:ELDN)

ELDN Stock Price History

ELDN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

ELDN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™